Cobra Biologics To Manufacture Algeta Antibody

Cobra Biologics and Algeta ASA have entered a new contract manufacturing partnership for Algeta’s fourth Targeted Thorium Conjugate (TTC) program focusing on the development of an undisclosed monoclonal antibody targeting hematological cancer cells.
 
Cobra will provide cell line development through its maxXpress service, GMP cell banking, analytical and process development, scale-up, toxicology and GMP production, as well as stability studies.
 
Peter Coleman, chief executive officer of Cobra Biologics, said, “We are delighted that Algeta has chosen Cobra as the manufacturer of a monoclonal antibody. Algeta’s contract forms part of a very successful year where we are seeing significant expansion in our antibody contract manufacturing as customers see the advantages Cobra’s comprehensive services provide.”